Zacks: Brokerages Expect Galectin Therapeutics Inc. (NASDAQ:GALT) to Announce -$0.09 EPS
Analysts forecast that Galectin Therapeutics Inc. (NASDAQ:GALT) will report ($0.09) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Galectin Therapeutics’ earnings. The lowest EPS estimate is ($0.10) and the highest is ($0.07). Galectin Therapeutics posted earnings per share of ($0.07) in the same quarter last year, which indicates a negative year over year growth rate of 28.6%. The firm is expected to report its next quarterly earnings report on Tuesday, November 12th.
According to Zacks, analysts expect that Galectin Therapeutics will report full-year earnings of ($0.37) per share for the current year, with EPS estimates ranging from ($0.47) to ($0.27). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.46) per share, with EPS estimates ranging from ($0.51) to ($0.41). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Galectin Therapeutics.
Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04.
Shares of Galectin Therapeutics stock traded up $0.20 on Friday, hitting $3.79. The company’s stock had a trading volume of 239,689 shares, compared to its average volume of 348,271. The company has a market capitalization of $215.76 million, a P/E ratio of -9.97 and a beta of 3.04. Galectin Therapeutics has a 52-week low of $2.94 and a 52-week high of $6.98. The firm has a fifty day moving average price of $3.44 and a 200-day moving average price of $4.17.
A number of hedge funds have recently bought and sold shares of the stock. Vivaldi Capital Management LLC acquired a new stake in Galectin Therapeutics during the 2nd quarter valued at $44,000. Commonwealth Equity Services LLC raised its holdings in shares of Galectin Therapeutics by 25.1% in the second quarter. Commonwealth Equity Services LLC now owns 15,247 shares of the company’s stock worth $63,000 after acquiring an additional 3,059 shares during the last quarter. Centaurus Financial Inc. raised its holdings in shares of Galectin Therapeutics by 20,098.8% in the second quarter. Centaurus Financial Inc. now owns 16,563 shares of the company’s stock worth $69,000 after acquiring an additional 16,481 shares during the last quarter. Amussen Hunsaker Associates LLC purchased a new stake in shares of Galectin Therapeutics in the second quarter valued at $71,000. Finally, D. E. Shaw & Co. Inc. lifted its position in shares of Galectin Therapeutics by 19.3% in the second quarter. D. E. Shaw & Co. Inc. now owns 19,498 shares of the company’s stock valued at $81,000 after acquiring an additional 3,148 shares in the last quarter. 14.99% of the stock is currently owned by hedge funds and other institutional investors.
Galectin Therapeutics Company Profile
Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
Featured Article: What Are Cryptocurrencies?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.